AI Article Synopsis
- - A survey was conducted among 65 neuro-oncology providers across the USA to understand their views on patients accessing electronic records online.
- - 58% of providers reported frequent patient inquiries about notes and findings outside of office visits, while a majority (54%) believed not all lab results should be released automatically.
- - 97% of providers expressed concerns that patients might experience significant distress from viewing test results before their appointments, supporting their cautious stance on immediate result accessibility.
Article Abstract
To evaluate the neuro-oncology providers' experience with patient online access to electronic records. Cross-sectional survey for physicians and advanced care providers within the field of neuro-oncology in the USA. 65 providers completed the survey, from all major regions of the USA. 58% reported that at least once per month, patients contacted them outside of an office visit about provider notes or a laboratory or imaging finding accessed online. 54% of providers did not think that all laboratory results should be released automatically, and only 25% of providers thought that all radiology reads should be released immediately. 97% thought that some patients suffered substantial distress viewing test results prior to appointments. Qualitative responses aligned with the quantitative results. Most neuro-oncology providers are concerned about the immediate release of laboratory and imaging findings to patients without guidance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152585 | PMC |
| http://dx.doi.org/10.1080/20450907.2024.2352414 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis.
Front Neurol
December 2024
Precision Medicine Laboratory, Sub-Direction of Research Unit, INCan, Mexico City, Mexico.
Background: This systematic review and meta-analysis investigated the relationship between somatic oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma.
Methods: We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of variants was assessed. We conducted searches in multiple databases.
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
Nat Commun
December 2024
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Glioblastoma is immunologically "cold" and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we enrolled an additional 25 patients with a primary endpoint of evaluating the cell cycle gene signature associated with neoadjuvant pembrolizumab and performed bulk-RNA seq on resected tumor tissue (NCT02852655).
View Article and Find Full Text PDFEvaluation of myelin content in the spinal cord of patients with multiple sclerosis: A positron emission tomography study.
Mult Scler Relat Disord
December 2024
Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina-FMUSP, Universidade de São Paulo, São Paulo 05403-911, SP, Brazil. Electronic address:
Background: Multiple sclerosis (MS) is divided into Relapsing-Remitting (RRMS) and Progressive (PMS) phenotypes, both associated with spinal cord (SC) damage. MS-related disability and SC atrophy are not yet fully understood and can differ across phenotypes. A combined approach using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) could provide a broader understanding of myelin changes in the cervical SC (CSC) in different MS phenotypes and the associations with disability.
View Article and Find Full Text PDFNanopore Sequencing as a Cutting-Edge Technology for Medulloblastoma Classification.
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFTherapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor.
Neuro Oncol
December 2024
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.
Background: NF2-related schwannomatosis (NF2-SWN) is associated with multiple benign tumors in the nervous system. NF2-SWN, caused by mutations in the NF2 gene, has developed into intracranial and spinal schwannomas. Because of the high surgical risk and frequent recurrence of multiple tumors, targeted therapy is necessary.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!